NYSE:TMOLife Sciences
How Investors May Respond To Thermo Fisher Scientific (TMO) Deepening Its Role In Late‑Stage mRNA Manufacturing
In late June and early July 2026, Arcturus Therapeutics announced a collaboration with Thermo Fisher Scientific, under which Thermo Fisher will supply integrated Phase 3 manufacturing, clinical research and potential commercial manufacturing services for ARCT-032, an investigational mRNA therapy for cystic fibrosis.
This agreement aligns Thermo Fisher even more closely with cutting-edge mRNA and rare disease workflows, expanding its role as an end-to-end development and manufacturing...